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Disseminated metastatic disease, including brain metastases, is commonly encountered in malignant melanoma. The classical
treatment approach for melanoma brain metastases has been neurosurgical resection followed by whole brain radiotherapy.
Traditionally, if lesions were either too numerous or surgical intervention would cause substantial neurologic deﬁcits, patients
were either treated with whole brain radiotherapy or referred to hospice and supportive care. Chemotherapy has not proven
eﬀective in treating brain metastases. Improvements in surgery, radiosurgery, and new drug discoveries have provided a wider
range of treatment options. Additionally, recently discovered mutations in the melanoma genome have led to the development of
“targeted therapy.” These vastly improved options are resulting in novel treatment paradigms for approaching melanoma brain
metastases in patients with and without systemic metastatic disease. It is therefore likely that improved survival can currently be
achieved in at least a subset of melanoma patients with brain metastases.
1.Introduction
It is estimated that metastatic melanoma was responsible for
more than 8700 caner-related deaths in the United States
in 2010 [1]. Melanoma ranks fourth in the incidence of
brainmetastases,behind lung,breast,andunknown primary
cancers [2]. In addition, metastatic melanoma patients
overall have a median survival of only 6–10 months and a 5-
yearsurvivaloflessthan10%[3].Therehasbeenvirtuallyno
improvement in survival of those patients in the past several
decades [3]. The trend toward targeted therapies [4], novel
immunotherapeutic agents [5], stereotactic radiosurgery,
and improved neurosurgical interventions give great hope to
improving this trend in the coming years.
2. Screening
In our own institutional experience, the risk of brain
metastasis in malignant melanoma is approximately 30% at
presentation of metastatic disease and may rise to 60%
over the next two years in surviving patients [6]. This risk
increases substantially with disease duration, as up to 75%
of Stage IV melanoma patients are found to have brain
metastases at autopsy [7–10]. The implication of this ﬁnding
is that brain metastases are an almost inevitable part of the
disease process, if patients survive long enough. Therefore,
the potential development of brain metastases needs to be
anticipated in both staging and follow-up strategies. Further
evidence of the high risk of brain metastases even in earlier
stage disease can be drawn from the recently completed
Southwest Oncology Group S0008 adjuvant therapy study.
In these Stage IIIb and IIIc patients, there was a 16% isolated
CNS failure rate within the ﬁrst 2 years as the initial site
of relapse (Samlowski et al., manuscript in preparation).
Even with such a high and alarming incidence, no standard
screeningrecommendationscurrentlyexistforStageIIIorIV
melanoma patients to detect presymptomatic disease. This
is in part because of the increasingly outdated perception2 Journal of Skin Cancer
that brain metastases represent a terminal event. This has
discouraged physicians from attempts at early detection.
Patients presenting with neurologic symptoms, such as
seizure or hemiplegia, are commonly found to have either
large (greater than 4cm) or numerous (greater than 7)
lesions. These clinical presentations are very diﬃcult to treat
and generally become palliative situations.
In contrast to this, less numerous and smaller (<2cm)
lesions encountered in asymptomatic patients are much
more readily and eﬀectively treated. It has been shown that
MRIscanswithgadoliniumcontrastaresuperiortoCTscans
when investigating for brain metastases [11]. Unfortunately,
there are no randomized clinical trials, to date, to deﬁne
the optimal screening strategy (e.g., timing of scans and
duration of followup) that would lead to eﬃcient and
cost-eﬀective detection. Another caveat is a need for these
studies to demonstrate that earlier detection actually leads
to improved functional outcome and survival, rather than
apparent diﬀerences induced by lead-time bias. With current
improvements in therapy, it is time, in our opinion, to
identify high-risk patients and begin such studies.
3. PalliativeTherapy
When dealing with metastatic brain lesion, neurologic
symptoms often present suddenly, including devastating
headaches, dizziness, and seizures. This may be due to
the development of peritumoral edema or bleeding into
previouslysilentmetastases.Theinitialtreatmentisgenerally
oralorintravenousglucocorticoids.Theiranti-inﬂammatory
activity helps to reduce peritumoral edema and swelling
and prevent further neurological deﬁcits [12]. Antiepileptic
drugs are indicated for treatment of patients who have
experienced seizures secondary to brain metastasis [13].
However, studies have shown no beneﬁt in prophylactic
treatment of patients with antiepileptic medications. These
medications can produce both side eﬀects and potential
interactions with chemotherapeutic agents [14].
4.SurgicalResection
Treatment of brain metastases has historically been based on
the use of surgical resection, when possible. The considera-
tion of surgical resection is dependent upon the number of
lesions, the overall state of systemic disease and symptoms
at the time of diagnosis. In general, patients with minimal
or no systemic disease, one or two superﬁcial metastases,
and excellent functional capacity will beneﬁt from surgery.
I nt h i sv e r ys m a l lg r o u po fp a t i e n t s( p e r h a p s5 %o v e r a l l ) ,
surgical intervention has been shown to improve quality of
l i f e ,a sw e l la ss u r v i v a l[ 10, 15]. Factors adversely aﬀecting
the decision to perform surgery include the size of the tumor
(greater than 2cm) and the location, (the ability to resect
lesions without signiﬁcant neurologic sequelae) [16, 17].
This surgical decision-making process is aided by current
technology, using stereotactic localization of the lesion at the
time of surgery [15]. Additionally, intraoperative functional
mapping may help to decrease the risk of neurologic
sequelae at the time of resection [18, 19]. It should be
noted that surgical resection may also beneﬁt the more
severely symptomatic patients, as excision of lesions causing
signiﬁcant edema or herniation can have a valuable palliative
eﬀect. After surgery, postoperative WBRT has been shown to
lead to longer functional independence for the patients, with
decreasingtheriskofrelapsingattheCNSresectionsite[20].
5. Whole Brain Radiotherapy (WBRT)
Traditionally, whole brain radiotherapy (e.g., 30Gy in 10
fractions over 2 weeks elapsed time) has become a de
facto (but not evidence-based) standard treatment for brain
metastasis. Some patients may have signiﬁcant palliation of
symptoms following treatment. Melanoma has traditionally
been considered radioresistant to these treatment doses,
however [21]. A number of series have established a median
survival of 3-4 months. For example, a large recent series
from the Sydney Melanoma Unit, encompassing close to
700 patients, showed that resected patients, with or without
WBRT had a median survival of 8.7 to 8.9 months, where as
patients treated solely with WBRT had a median survival of
only3.4months.Thisisclearlyapooroutcome,althoughthe
patient selection process for surgery versus radiotherapy was
notdescribed.Ashasbeenseenwithalltreatmentmodalities,
a patient with excellent performance status and no systemic
metastatic disease, and/or a single lesion relapse, WBRT
haveasomewhatbetteroutcome(termedRecursivePartition
Class 1) [22]. In reality, these patients are very uncommon
in a medical oncology clinic, where the vast majority of
patients have active systemic metastatic disease (Class II or




In contrast to large (>4cm) lesions, smaller metastatic
lesions have become easily treated via radiosurgery. In these
situations solitary or multiple lesions can be treated with
either stereotactic radiosurgery (SRS) or Gamma-knife (GK)
treatment. At present, no head-to-head comparisons exists
randomizing patient to SRS versus GK. Based on radiobi-
ology studies, it is currently believed that patient outcomes
should be comparable between these approaches. The major
beneﬁt of radiosurgery is that it allows for treatment of brain
lesions that would otherwise be inoperable, including lesions
in deep structures and close to functionally critical brain
structures. This can be accomplished due to the rapid drop-
oﬀ of radiation dose at the margin of the treatment volume
and the capability of computerized MRI-based dosimetry
planning.Insmallcaseserieslocalcontrol,survivalfollowing
radiosurgery (either SRS or GK) has been quite encouraging
[25–39].
Aswithallmodalitiestherearepreferredparameterssuch
as lesion size (ideally under 3cm) and a total number of
lesions (7 or less) that make radiosurgery most eﬀective.
The maximum number of lesions that can be eﬀectivelyJournal of Skin Cancer 3
treated is still evolving, but is generally functionally deﬁned
as the number that can be eﬀectively treated in about 1
hour of patient immobilization. There may be an impor-
tant biological issue, to consider as well, as patients with
oligometastatic disease (1–3 metastases) may have a diﬀerent
biologyandoutcometothosewithmany(10–20)metastases.
The optimal break point in deciding whether to employ
radiosurgery or WBRT as the primary treatment modality
remains to be better deﬁned as radiosurgery technology
evolves to allow more rapid treatment of increasing numbers
of lesions.
7.Should WBRT Automatically Be Added
afterSRS?
Historically, WBRT was used to treat brain metastases and
after the development of SRS/GK, these were initially added
to boost the radiation dose to larger lesions, which were
unlikely to be controlled by WBRT alone. It soon became
apparent that primary SRS/GK of smaller lesions provided
excellent long-term lesion control as a primary treatment,
and that many of these patients did not appear to require
additional CNS therapy (either WBRT or surgery) [40]. This
has led to an ongoing debate about whether GK/SRS should
be followed by immediate WBRT for treatment of patients
with melanoma brain metastases, or whether WBRT could
be deferred. There have now been four randomized clinical
trials including patients with 1–3 brain metastases from a
variety of cancers. These studies have generally shown that
local control at the SRS-/GK-treated site is not improved by
WBRT, but that the development of new brain metastases
is signiﬁcantly decreased by immediate addition of WBRT
[38, 41–43]. Overall survival does not appear to have been
aﬀectedby immediate WBRT.This is becausedelayed salvage
with additional SRS/GK [44, 45], or delayed WBRT, is
possible (in the <50% of patients who progress in the CNS)
[46]. Thus, quite a few investigators have concluded that
delaying WBRT may be appropriate for some patients, with
the caveat that these patients need to be followed closely with
the intent of early retreatment at CNS progression [46, 47].
This has the potential to decrease neuropsychiatric sequelae
and memory loss from radiotherapy in the increasing
number of long-term survivors of brain metastases [48],
as in our experience 50% of patients never require salvage
therapy [6]. In addition, the only patients who developed
radiation necrosis as a treatment complication in our series
h a dr e c e i v e db o t hS R Sa n dW B R T[ 6].
8. Systemic Therapy
Systemic therapy has historically not been eﬀective in
melanoma therapy and, therefore, has rarely been utilized as
primary treatment for metastatic brain lesions [49]. How-
ever, most patients with brain metastases also have active
systemic metastases. Once brain metastases are controlled
(e.g., with surgery, or SRS/GK), failure to treat systemic
disease results in invariable progression and death of the
patient (both due to reseeding of the CNS and systemic
progression). This was particularly true in the era of inef-
fective chemotherapy. Remarkably, if even modestly eﬀective
IL-2-based immunotherapy was added after control of CNS
metastases, prolonged survival appeared to be achievable
in some patients. We initially demonstrated this principle
by using biochemotherapy after SRS treatment of brain
metastases and showed that median survival of over 1 year
could be achieved, with 15% of patients alive at 3 years [50].
This observation is currently being recapitulated in clinical
trials of the CTLA-4 monoclonal antibody ipilimumab.
In these studies, patients with SRS/GK controlled brain
metastases have been included and have shown signiﬁcant
survival prolongation. These trials have included patients
with apparent CNS responses to ipilimumab therapy [5, 51,
52]. What appears most interesting is that if the CNS lesions
can be eﬀectively controlled for an extended period (perhaps
18–24 months), eventual long-term CNS control appears to
be achievable, as was previously seen with biochemotherapy
[50].
9.TargetedTherapies
A series of somatic genetic mutations has been identiﬁed in
melanoma cells, leading to the research in speciﬁc targeted
therapies. These include mutations in NRAS, BRAF, C-KIT
(in cutaneous melanoma) [53], GNAQ, and GNA11 (in
ocular melanoma) [54, 55], as well as in tumor suppressor
genessuchasPTENandp16[56].AsinglemutationinBRAF
(V600E) is present in about 50–60% of human cutaneous
melanomas[57].Thissubstitutiontriggersakinase-signaling
cascade that can lead to cell growth, tissue invasion, and
ultimately metastasis [57, 58]. While inhibitors of the wild-
type B-RAF are not clinically active in melanoma [59],
inhibitorsoftheV600Emutationarehighlyactiveinpatients
whose tumor expresses this mutation [4].
Unfortunately, most early B-RAF V600E inhibitor trials
were designed to speciﬁcally exclude patients with brain
metastases. In October of 2010, at the 35th Congress
of the European Society for Medical Oncology (ESMO),
a phase I/II clinical trial involving the newly developed
GSK2118436 V600E BRAF inhibitor was presented. This
trial allowed enrollment of a cohort of 10 patients with
V600 BRAF positive melanomas and brain metastases. All
patients experienced control of their brain metastases, with
90% experiencing a signiﬁcant decrease in lesions size. This
response was seen in brain metastases measuring 3mm or
larger in diameter, with an estimated reduction of between
20 and 100%. This is the ﬁrst targeted agent that has shown
objective responses in the CNS. This observation will be
followed up with larger clinical trials in the United States and
internationally.
10. Conclusions
Treatment of brain lesions in metastatic melanoma patients
remainsanongoingchallenge.Astheincidenceofmelanoma
has increased, so has the need to confront this problem.
We have begun to rethink our approaches, including the
screening of appropriate patient populations (overviewed4 Journal of Skin Cancer
Table 1: Potential management strategies for melanoma patients with brain metastases.
Brain metastases Largest lesion Symptomatic∗ Suggested CNS treatment Systemic metastases Systemic therapy§
1 <3cm yes or no surgery†GK or SRS• no not suggested
1 >4cm yes or no surgery† no not suggested
2–5 <4cm yes or no GK or SRS no no
2–5 <4cm yes or no GK or SRS yes yes¶
>5 <4cm yesorno WBR T  no no
>5 <4cm yesorno WBR T  yes yes¶
∗Palliative glucocorticosteroid administration should be considered to decrease symptomatic edema, if present.
†Resectability may depend on location related to critical brain structures.
•GK and SRS are probably equivalent to surgical resection for lesion control if <2cm.
§The majority of these patients do not progress with systemic disease and there is little evidence that early systemic treatment improves either the risk of
systemic relapse or helps control CNS metastases.
¶Patients should have CNS lesions treated and controlled ﬁrst, potentially eﬀective agents include immunotherapy (ipilimumab, possibly IL-2) and targeted
therapy (B-RAF inhibitor, etc.), if the appropriate activating mutation is present in tumors.
Stereotactic boost to dominant lesions > 1cm after WBRT may increase local lesion control and survival in patients with early CNS control and controlled
systemic disease based on randomized trials.
in Table 1). There have been reﬁnements in traditional
modalities, such as neurosurgery, as well as development
of stereotactic guidance and functional mapping techniques
that have enhanced their eﬀectiveness. The evolution of
computer-image-guided radiosurgery has further improved
treatment options in radioresistant cancers and limited
collateralinjurytonormaltissuestructures.Eﬀectivesequen-
tial or concurrent therapy of CNS metastases and sys-
temic disease has proven to be possible, especially with
the development of new and active immunotherapy and
targeted therapeutic agents. There remains more work to be
done, especially with improving local CNS control at the
treated sites (the eventual cause of about 1/3 of mortality),
development of new CNS metastases (resulting in another
1/3 of patient deaths), and systemic treatment failures (the
remaining 1/3 of patient deaths). Close followup of treated
patients is essential, as retreatment of the CNS is frequently
possible, with long-term salvage as a potential goal in some
patients. With the continuing evolution of therapy and
continued clinical trials, hope of an entire new spectrum of
therapeutic options is within our grasp. We must remain
steadfast in our pursuit of these attainable goals through
continued high-quality patient-centered research.
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